certifies that
Mutombo Kankonde, MD
2400 Trawood Drive
Suite 303
El Paso, TX 79936
2400 Trawood Drive
Suite 303
El Paso, TX 79936
has participated in the enduring material titled
Mechanisms and Actions of HER2-Targeting Agents in Breast Cancer
April 1, 2013
and is awarded
0.50
AMA PRA Category 1 Credit(s)™.
Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medscape, LLC is accredited by the Accreditation Council for
Continuing Medical Education (ACCME) to provide continuing medical
education for physicians.
For information on
applicability and acceptance of continuing education credit for this
activity, please consult your professional licensing board.
Certificate Number: 42523061 | Cyndi Grimes Director, Continuing Medical Education Medscape, LLC |
==============================================================
Options to Her2 positive tumors after Herceptin!
T-DM1
pertuzumab
lapatinib +Xeloda
combination with Everolimus Neratinib
Options to Her2 positive tumors after Herceptin!
T-DM1
pertuzumab
lapatinib +Xeloda
combination with Everolimus Neratinib
No comments:
Post a Comment